Dr Jeremy Braybrooke
BSc, BM, FRCP, PhD
Senior Clinical Research Fellow
Jeremy is a Consultant Medical Oncologist and clinical lead for oncology at University Hospitals Bristol NHS Foundation Trust. He trained in Medical Oncology at the Cancer Research UK Medical Oncology unit in Oxford. During this time he completed a PhD in DNA damage and repair pathways. Jeremy has worked in Bristol since 2003 and developed a large research focussed clinical practice specialising in breast and testicular cancers. Jeremy sits on a NICE Technology Appraisal Committee evaluating new medicines and is a member of the Royal College of Physicians Specialist Advisory Committee for medical oncology training. He is actively involved in clinical research and since 2016 has worked part time as a Senior Clinical Research Fellow within EBCTCG.
The mutational frequency of BRAF and KRAS in low-grade serous testicular neoplasms-a case series.
Gwiti P. et al, (2017), Histopathology, 71, 686 - 692
The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
Kuchel A. et al, (2016), Br J Cancer, 114, 731 - 736
Paraneoplastic tumefactive demyelination with underlying combined germ cell cancer.
Broadfoot JR. et al, (2015), Pract Neurol, 15, 451 - 455
Patients' experiences following breast cancer treatment: an exploratory survey of personal and work experiences of breast cancer patients from three European countries.
Braybrooke JP. et al, (2015), Eur J Cancer Care (Engl), 24, 650 - 661
Medical and oncological management of malignant mesothelioma.
Bibby AC. et al, (2015), Br J Hosp Med (Lond), 76, 384 - 389